Therapeutic peptides, as well as broader biologics and biotherapeutics, are rapidly reshaping the treatment landscape for chronic diseases, offering precision, potency and specificity that small molecules often can’t match. Among peptide-based therapeutics, such as, Glucagon-Like Peptide-1 (GLP-1) receptor agonists – including semaglutide and liraglutide – have emerged as game changers in managing type 2 diabetes,…
Sandoz’s Hyrimoz to challenge AbbVie’s Humira dominance
The generic and biosimilar company Sandoz, a Novartis (NYSE:SIX) subsidiary, has received FDA approval for its Humira biosimilar Hyrimoz (adalimumab-adaz) injection. AbbVie’s (NYSE:ABBV) megablockbuster Humira is a biologic medication with indications for an array of autoimmune conditions, including rheumatoid arthritis, Crohn’s disease and psoriasis. Sandoz’s biosimilar will likely be priced significantly lower than Humira’s. This…